Tetrahydrocannabinol In A Method Of Treating Glaucoma

Jacob Bell

New Member
Patent References

3668224

3728360

3734930

3799946

3920809

Abstract
Significant success in alleviating the symptoms of glaucoma is achieved by orally administering to a glaucoma sufferer a therapeutically effective, but sub-psychotropic dose of tetrahydrocannabinol (THC), which is the most active ingredient in marijuana. The most significant results are achieved when this form of treatment is combined with conventional types of anti-glaucoma treatment, although in a limited number of cases, THC therapy alone proved successful. Also disclosed is a dosage unit form for THC comprising a suitable dose of THC in combination with an innocuous diluent such as fructose.

Other References

The Merck Index, 8th ed. pp. 830, 831 and 833 (1968) Merck & Co
Ophthalmologica 168 366-369 (1974)--D. Shapiro--The Ocular Manifestations of the Cannabinols, Newsweek, 11/8/76, Pot and Glaucoma
Chem. Abst. 83 158,044(r) (1975)--Purnell et al. "A9 -Tetrahydrocannabinol . . . in Man"
Chem. Abst. 84 130,270(h) (1976)--Green et al. Interaction of . . . Tetrahydrocannabinol in the Eye"


Source: Tetrahydrocannabinol in a method of treating glaucoma - US Patent 4189491
 
Back
Top Bottom